title: Rituximab with peripheral blood stem cell transplantation in CD20 lymphoproliferative disorders.
authors.forename: P
authors.initials: P
authors.lastname: Mazza
authors.forename: G
authors.initials: G
authors.lastname: Palazzo
authors.forename: B
authors.initials: B
authors.lastname: Amurri
authors.forename: G
authors.initials: G
authors.lastname: Pricolo
authors.forename: A
authors.initials: A
authors.lastname: Prudenzano
authors.forename: L
authors.initials: L
authors.lastname: Stani
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007937:Leukapheresis / Q000379:methods; D008232:Lymphoproliferative Disorders / Q000188:drug therapy* / Q000276:immunology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual / Q000188:drug therapy; D012074:Remission Induction; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab